ARCT News and Press, Arcturus Therapeutics Ltd. From 05/10/21

ARCT-021 Phase 2 interim data showed favorable safety profile and greater than 90% seroconversion after a single dose; data supports advancement into Phase 3 In negotiations with multiple regulatory authorities regarding ARCT-021 Phase 3 study program Continued progres...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Arcturus has a Covid-19 vaccine in development, funded by the Singapore government. It has shown some decent results in early trials. However, the market is underwhelmed by these results. For further details see: Arcturus: Developing A Covid-19 Vaccine But Too Little, To...

The following slide deck was published by Arcturus Therapeutics Holdings Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Arcturus Therapeutics Holdings Inc. 2020 Q4 - Results - Earnings Call Presentation

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2020 Earnings Conference Call March 01, 2021 04:30 PM ET Company Participants Neda Safarzadeh - Head-Investor Relations, Public Relations & Marketing Joseph Payne - President & Chief Executive Officer Ooi Eng Eong - Deputy Director-Emergin...

Arcturus Therapeutics (ARCT): Q4 GAAP EPS of -$1.25 misses by $0.33.Revenue of $2.2M (-25.9% Y/Y) misses by $0.12M.Shares +3.7%.Press Release For further details see: Arcturus Therapeutics EPS misses by $0.33, misses on revenue

ARCT-021 single-shot COVID-19 STARR™ mRNA vaccine to be advanced to Phase 3 clinical development – on track to initiate Phase 3 study in Q2 ARCT-021 single shot immunogenicity profile compares favorably with new data generated from recipients of a single dose of ...

Illumina and its short reading technology pushed the sequencing costs down during the last decade. Long reads and artificial intelligence are improving the sequencing and will likely keep driving the costs lower. Several companies are building business models around these technolo...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...